Prior to joining Banyan Biomarkers, Ms Hague was the director of clinical research at Abbott Molecular.
Banyan Biomarkers said that Ms Hague has 20 years of clinical research and regulatory affairs experience. She has directed industry sponsored in-vitro diagnostic clinical trials for genetic diseases, oncology, and infectious diseases as well as NIH sponsored treatment trials for pediatric and maternal AIDS.
In Banyan Biomarkers, Ms Hague is expected to take up the responsibility for bringing the company’s proprietary immunoassays for traumatic brain injury through clinical trials and the FDA’s pre-market approval process.
Jackson Streeter, chief medical officer and CEO of Banyan Biomarkers, said: “Lynda Hague is a seasoned healthcare executive with direct clinical and regulatory experience. She has extensive knowledge in the design and implementation of clinical trials and we are pleased to welcome her to Banyan Biomarkers.”
